Cell and gene therapy venture capital and public funding deal count vs Antibody-drug conjugate trial starts
In 2023, cell and gene therapy venture capital and public funding deal count worldwide stood at 96, against 233 for antibody-drug conjugate trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Cell and gene therapy venture capital and public funding deal count and Antibody-drug conjugate trial starts
Unit: count · 9 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Cell and gene therapy venture capital and public funding deal count | 2023 | Actual | 96 |
| Cell and gene therapy venture capital and public funding deal count | 2022 | Actual | 97 |
| Cell and gene therapy venture capital and public funding deal count | 2021 | Actual | 127 |
| Antibody-drug conjugate trial starts | 2025 | Actual | 349 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 282 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 233 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 176 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 145 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 101 |
Shared periods
Side by side
3 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Cell and gene therapy venture capital and public funding deal count
Number of venture capital and public funding transactions for cell and gene therapies in a given year.
3 observations charted in Global · source organisations: IQVIA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring